EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Renal Protection of Mineralocorticoid Receptor Antagonist, Finerenone, in Diabetic Kidney Disease

Dong-Lim Kim, Seung-Eun Lee, Nan Hee Kim

Endocrinology and Metabolism · 2023

DOI: 10.3803/enm.2022.1629 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Endocrinology and Metabolism, 2023. Verfasst von Dong-Lim Kim und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Endocrinology and Metabolism, Department of Internal Medicine, Konkuk University School of Medicine, Seoul, Korea. Hauptthemen laut MEDLINE: Diabetic Nephropathies, Diabetes Mellitus, Type 2, Sodium-Glucose Transporter 2 Inhibitors, Renal Insufficiency, Chronic. Die Arbeit wurde bisher 48-mal zitiert (Crossref) und nennt 85 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chronic kidney disease (CKD) is the most common cause of end-stage renal disease in patients with type 2 diabetes mellitus (T2DM). CKD increases the risk of cardiovascular diseases; therefore, its prevention and treatment are important. The prevention of diabetic kidney disease (DKD) can be achieved through intensive glycemic control and blood pressure management. Additionally, DKD treatment aims to reduce albuminuria and improve kidney function. In patients with T2DM, renin-angiotensin-aldosterone system inhibitors, sodium glucose cotransporter 2 inhibitors, and glucagon-like peptide-1 receptor agonists can delay the progression of DKD. Hence, there is a need for novel treatments that can effectively suppress DKD progression. Finerenone is a first-in-class nonsteroidal mineralocorticoid receptor antagonist with clinically proven efficacy in improving albuminuria, estimated glomerular filtration rate, and risk of cardiovascular events in early and advanced DKD. Therefore, finerenone is a promising treatment option to delay DKD progression. This article reviews the mechanism of renal effects and major clinical outcomes of finerenone in DKD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetic NephropathiesDiabetes Mellitus, Type 2Sodium-Glucose Transporter 2 InhibitorsRenal Insufficiency, ChronicHumansMineralocorticoid Receptor AntagonistsAlbuminuriaDouble-Blind MethodKidneyNaphthyridines

Stichwörter der Autor:innen

Diabetes mellitus, type 2Diabetic nephropathiesFinerenoneMineralocorticoid receptor antagonistsRenal insufficiency, chronic

Substanzen

Mineralocorticoid Receptor AntagonistsSodium-Glucose Transporter 2 InhibitorsfinerenoneNaphthyridines

Autor:innen und Institutionen

  • Division of Endocrinology and Metabolism, Department of Internal Medicine, Konkuk University School of Medicine, Seoul, Korea.
  • Department of Internal Medicine, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Korea.
  • Division of Endocrinology and Metabolism, Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea.

Zitieren

APA

Kim, D. L., Lee, S. E., & Kim, N. H. (2023). Renal Protection of Mineralocorticoid Receptor Antagonist, Finerenone, in Diabetic Kidney Disease. Endocrinology and Metabolism. https://doi.org/10.3803/enm.2022.1629

Vancouver

Kim DL, Lee SE, Kim NH. Renal Protection of Mineralocorticoid Receptor Antagonist, Finerenone, in Diabetic Kidney Disease. Endocrinology and Metabolism. 2023. doi:10.3803/enm.2022.1629

BibTeX
@article{Kim2023,
  author = {Kim, Dong-Lim and Lee, Seung-Eun and Kim, Nan Hee},
  title = {Renal Protection of Mineralocorticoid Receptor Antagonist, Finerenone, in Diabetic Kidney Disease},
  journal = {Endocrinology and Metabolism},
  year = {2023},
  doi = {10.3803/enm.2022.1629}
}
Kostenlos starten →